Inimmune announces successful Phase 1 clinical results for disease modifying allergy treatment, INI-2004

May 15, 2024•1 min read

Inimmune, a leading clinical stage biotech company focused on the development of novel vaccine adjuvants, immunotherapies and delivery systems, has announced the top line results from its Phase 1b Multiple Ascending Dose (MAD) study of INI-2004 in people suffering with Allergic Rhinitis.

Montana BioScience Alliance

Montana BioScience Alliance is the statewide organization dedicated to advancing and advocating for Montana’s bioscience industry. The Alliance connects researchers, companies, and policymakers to strengthen research, support responsible policy, and drive economic growth across the state.

Back to Blog